(Q37598264)

21 August 2017

1 reference

title

Agomelatine, a melatonin agonist with antidepressant properties (English)

1 reference

21 August 2017

0 references

Steven L Dubovsky

1

1 reference

21 August 2017

Calvert Warren

series ordinal

2

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 October 2009

1 reference

Expert Opinion on Investigational Drugs

21 August 2017

published in

1 reference

21 August 2017

volume

18

1 reference

21 August 2017

issue

10

1 reference

21 August 2017

page(s)

1533-1540

1 reference

Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543780903292634

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthre

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903292634

Predictors of relapse into major depressive disorder in a nonclinical population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903292634

Extrapyramidal symptoms associated with cyclic antidepressant treatment: a review of the literature and consolidating hypotheses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903292634

Bleeding and selective serotonin reuptake inhibitors in childhood and adolescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903292634

Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903292634

Network pharmacology: the next paradigm in drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903292634

From magic bullets to designed multiple ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903292634

Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903292634

Intracellular mechanisms of antidepressant drug action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903292634

Limitations of current medical treatments for depression: disturbed circadian rhythms as a possible therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903292634

The interaction between the internal clock and antidepressant efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903292634

Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903292634

Pharmacology of a new antidepressant: benefit of the implication of the melatonergic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903292634

High-quality remission: potential benefits of the melatonergic approach for patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903292634

Agomelatine: a preliminary review of a new antidepressant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903292634

New selective ligands of human cloned melatonin MT1 and MT2 receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903292634

The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903292634

Agomelatine treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903292634

Agomelatine, a melatonin receptor agonist with 5-HT(2C) receptor antagonist properties, protects the developing murine white matter against excitotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903292634

Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903292634

Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903292634

Effects of melatonin and agomelatine in anxiety-related procedures in rats: interaction with diazepam

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903292634

Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903292634

Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903292634

Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903292634

A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903292634

Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903292634

Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903292634

Agomelatine in the treatment of seasonal affective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903292634

Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903292634

Major depressive disorder, sleep EEG and agomelatine: an open-label study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903292634

Fragmentation of sleep-wake cycle secondary to narcolepsy and Cheyne-Stokes respiration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903292634

Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903292634

Intracoronary ketanserin augments coronary collateral blood flow and decreases myocardial ischemia during balloon angioplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903292634

10.1517/13543780903292634

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference